Ivermectin | CAS# 70288-86-7 | antiboitics

MedKoo Cat#: 326779 | Name: Ivermectin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ivermectin is a medication that is effective against many types of parasites. It is used to treat head lice, scabies, river blindness, strongyloidiasis, and lymphatic filariasis, among others. Ivermectin and other avermectins (insecticides most frequently used in home-use ant baits) are macrocyclic lactones derived from the bacterium Streptomyces avermitilis. Ivermectin kills by interfering with nervous system and muscle function, in particular by enhancing inhibitory neurotransmission. Ivermectin is a mixture of mostly avermectin H2B1a (CAS# 71827-03-7) with some avermectin H2B1b (CAS# 70209-81-3), which are macrolides from STREPTOMYCES avermitilis.

Chemical Structure

Ivermectin

CAS# 70288-86-7

Theoretical Analysis

MedKoo Cat#: 326779

Name: Ivermectin

CAS#: 70288-86-7

Chemical Formula: C48H74O14 . C47H72O14

Exact Mass: 1736.0001

Molecular Weight: 1736.18

Elemental Analysis: C, 65.72; H, 8.48; O, 25.80

Price and Availability

Size	Price	Availability
100mg	USD 90.00	Ready to ship
200mg	USD 150.00	Ready to ship
500mg	USD 250.00	Ready to ship
1g	USD 350.00	Ready to ship
2g	USD 450.00	Ready to ship
5g	USD 850.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MK-933; Ivermectin; Ivomec; L 64047;1 Mectizan; MK 933; MK-0933; Noromectin; Pandex.

IUPAC/Chemical Name

22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b

InChi Key

SPBDXSGPUHCETR-VHJJIYNUSA-N

InChi Code

InChI=1S/C48H74O14.C47H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38;1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3;11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b13-12+,27-15+,32-14+;12-11+,26-14+,31-13+/t25?,26-,28-,30-,31-,33+,34?,35-,36-,37-,38?,39-,40+,41-,42-,43+,44-,45+,47+,48+;25-,27-,29-,30-,32+,33?,34-,35-,36-,37?,38-,39+,40-,41+,42-,43-,44+,46+,47+/m00/s1

SMILES Code

CCC([C@@H]1[C@@H](C)CC[C@]2(CC3C[C@@H](C/C=C(C)/[C@@H](O[C@H]4C[C@H](OC)[C@@H](OC5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)/C=C/C=C6CO[C@H]7[C@]\6(O)[C@H](C(O3)=O)C=C(C)[C@H]7O)O2)O1)C.C[C@H]8CC[C@@]9(O[C@@H]8C(C)C)CC%10C[C@@H](C/C=C(C)/[C@@H](O[C@H]%11C[C@H](OC)[C@@H](OC%12C[C@H](OC)[C@@H](O)[C@H](C)O%12)[C@H](C)O%11)[C@@H](C)/C=C/C=C%13CO[C@H]%14[C@]\%13(O)[C@H](C(O%10)=O)C=C(C)[C@H]%14O)O9

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C20B06B02

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Ivermectin (MK-933) is a broad-spectrum anti-parasite agent that is a specific inhibitor for Impα/β1-mediated nuclear import and bovine herpesvirus1 (BoHV-1) and has potent antiviral activity towards both HIV-1 and dengue virus.

In vitro activity:

It was next explored whether ivermectin suppresses the migration and invasion, two important characteristic features involved in cancer metastasis including ESCC. In wound healing assay, upon treatment with 2.5 μmol/L ivermectin for 24 hours, the migration of KYSE150 and KYSE30 cells that was dramatically suppressed, the inhibition was further enhanced after incubation with ivermectin for 48 hours (Figure 3A). Consistent with these results, transwell migration assay revealed that the migrative ability was greatly attenuated by ivermectin at the concentration of 2.5 μmol/L in both tested ESCC cell lines (Figure 3B). It was also explored whether ivermectin has a inhibitory effect on ESCC cell invasion by using transwell invasion assay. Interestingly, the data showed that ivermectin strongly diminished the invasion of KYSE150 and KYSE30 cells, compared with corresponding control groups (Figure 3C). Consistently, the protein levels of MMP‐9 and MMP‐2, two important family members of matrix metalloproteinases (MMPs), were greatly down‐regulated in a dose‐dependent manner in both KYSE150 and KYSE30 cells (Figure 3D). Collectively, these data suggest that ivermectin effectively suppresses the migration and invasion of ESCC cells. Reference: J Cell Mol Med. 2020 May; 24(9): 5387–5401. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205794/

In vivo activity:

To evaluate the effect of ivermectin on canine mammary tumor growth in vivo, CIPp cells were injected subcutaneously into BALB/c nude mice to establish xenograft tumors. After 3 weeks of ivermectin administration by intraperitoneal injection, all xenograft tumors were collected (Fig. 5a and Additional file 1: Figure S1A). The volume of tumors in ivermectin treatment group was lower than that in the control group at the end of treatment (Fig. 5b and Additional file 1: Figure S1B). Furthermore, immunohistochemistry analysis with the proliferation marker Ki67 was performed in tumor tissues (Fig. 5c and Additional file 1: Figure S1C), and a significant difference was observed between these two groups (Fig. 5d and Additional file 1: Figure S1D) (P<0.01). These data were in concordance with our in vitro data, and confirmed the inhibition of tumor growth by ivermectin in canine mammary tumor cells. Reference: BMC Vet Res. 2019; 15: 276. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679554/

	Solvent	mg/mL	mM
Solubility
	DMSO	75.0	43.20

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,736.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Jiang L, Wang P, Sun YJ, Wu YJ. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019 Jun 18;38(1):265. doi: 10.1186/s13046-019-1251-7. PMID: 31215501; PMCID: PMC6580523. 2. Chen L, Bi S, Wei Q, Zhao Z, Wang C, Xie S. Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma. J Cell Mol Med. 2020 May;24(9):5387-5401. doi: 10.1111/jcmm.15195. Epub 2020 Mar 31. PMID: 32237037; PMCID: PMC7205794. 3. Diao H, Cheng N, Zhao Y, Xu H, Dong H, Thamm DH, Zhang D, Lin D. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. BMC Vet Res. 2019 Aug 2;15(1):276. doi: 10.1186/s12917-019-2026-2. PMID: 31375107; PMCID: PMC6679554.

In vitro protocol:

In vivo protocol:

1. Diao H, Cheng N, Zhao Y, Xu H, Dong H, Thamm DH, Zhang D, Lin D. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. BMC Vet Res. 2019 Aug 2;15(1):276. doi: 10.1186/s12917-019-2026-2. PMID: 31375107; PMCID: PMC6679554. 2. Jiang L, Wang P, Sun YJ, Wu YJ. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019 Jun 18;38(1):265. doi: 10.1186/s13046-019-1251-7. PMID: 31215501; PMCID: PMC6580523.

1: Pampiglione S, Majori G, Petrangeli G, Romi R. Avermectins, MK-933 and MK-936, for mosquito control. Trans R Soc Trop Med Hyg. 1985;79(6):797-9. doi: 10.1016/0035-9203(85)90121-x. PMID: 3832491. 2: Focks DA, McLaughlin RE, Linda SB. Effects of ivermectin (MK-933) on the reproductive rate of Aedes aegypti (Diptera: Culicidae). J Med Entomol. 1991 Jul;28(4):501-5. doi: 10.1093/jmedent/28.4.501. PMID: 1941909. 3: Lancaster JL Jr, Simco JS, Kilgore RL. Systematic efficacy of ivermectin MK-933 against the lone star tick. J Econ Entomol. 1982 Apr;75(2):242-4. doi: 10.1093/jee/75.2.242. PMID: 6896882. 4: Awadzi K, Dadzie KY, Shulz-Key H, Haddock DR, Gilles HM, Aziz MA. The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis. Ann Trop Med Parasitol. 1985 Feb;79(1):63-78. PMID: 3838638. 5: Drummond RO, Whetstone TM, Miller JA. Control of ticks systemically with Merck MK-933, an avermectin. J Econ Entomol. 1981 Aug;74(4):432-6. doi: 10.1093/jee/74.4.432. PMID: 7320317. 6: Elliott DC, Julian AF. The removal of inhibited early fourth stage Ostertagia ostertagi from yearling cattle by MK 933, an ivermectin formulation. N Z Vet J. 1981 May;29(5):68-9. doi: 10.1080/00480169.1981.34803. PMID: 6946336. 7: Diop Mar I, Diallo S, Diallo JS, Ndir O, Badiane S. L'expérience sénégalaise sur l'efficacité de l'ivermectine (MK 933) dans le traitement de l'onchocercose humaine (etude comparative en double aveugle avec le citrate de diéthylcarbamazine) (DEC.C) [Senegalese experience with the efficacy of ivermectin (MK 933) in the treatment of human onchocerciasis (double-blind comparative study with diethylcarbamazine citrate) (DEC.C)]. Bull Acad Natl Med. 1986 Jan;170(1):149-55. French. PMID: 3527347. 8: Diallo S, Larivière M, Diop Mar I, N'Dir O, N'Diaye R, Badiane S, Porta M, Aziz M. Conduite au Sénégal des premières études d'efficacité et de tolérance de l'ivermectine (MK 933) dans l'onchocercose humaine [Management in Senegal of the 1st efficacy and tolerability studies of ivermectin (MK 933) in human onchocerciasis]. Bull Soc Pathol Exot Filiales. 1984 Mar-Apr;77(2):196-205. French. PMID: 6373039.

View History

Itramin tosilate

MedKoo CAT#: 412347

CAS#: 13445-63-1